slightly ahead of GSK and partner AnaptysBio with cobolimab, which is being tested alongside GSK’s PD-1 inhibitor Jemperli (dostarlimab) and docetaxel in the phase 3 COSTAR trial in advanced non ...
In a report released on March 24, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The company’s shares closed yesterday at $18.19.
Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund 301.67k Dec 31, 2024 0.98% 5,716,646 Fidelity Securities Fund-Fidelity Series Small Cap Opportunities Fund 269.44k Dec 31, 2024 0.88% ...
GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company ...
As of 3:08:37 PM EDT. Market Open.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback